OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 116 filers reported holding OCULAR THERAPEUTIX INC in Q4 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $211,021 | -3.2% | 67,204 | +59.1% | 0.00% | – |
| Q2 2023 | $217,907 | -2.8% | 42,230 | -0.7% | 0.00% | – |
| Q1 2023 | $224,070 | -29.2% | 42,518 | -62.2% | 0.00% | -100.0% |
| Q4 2022 | $316,434 | +486.0% | 112,610 | +767.4% | 0.00% | – |
| Q3 2022 | $54,000 | -62.0% | 12,982 | -63.3% | 0.00% | – |
| Q2 2022 | $142,000 | +0.7% | 35,342 | +24.5% | 0.00% | – |
| Q1 2022 | $141,000 | -6.6% | 28,395 | +30.7% | 0.00% | – |
| Q4 2021 | $151,000 | -76.7% | 21,720 | -66.4% | 0.00% | -100.0% |
| Q3 2021 | $647,000 | -22.2% | 64,682 | +10.2% | 0.00% | 0.0% |
| Q2 2021 | $832,000 | -22.1% | 58,675 | -9.8% | 0.00% | -50.0% |
| Q1 2021 | $1,068,000 | +5.7% | 65,077 | +33.4% | 0.00% | 0.0% |
| Q4 2020 | $1,010,000 | +134.3% | 48,786 | -13.8% | 0.00% | +100.0% |
| Q3 2020 | $431,000 | -29.3% | 56,615 | -22.7% | 0.00% | 0.0% |
| Q2 2020 | $610,000 | +365.6% | 73,210 | +244.4% | 0.00% | – |
| Q3 2017 | $131,000 | – | 21,256 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,932,607 | $40,643,000 | 15.56% |
| Lamond Capital Partners LLC | 711,533 | $14,964,000 | 15.19% |
| Polaris Venture Management Co. V, L.L.C. | 1,230,009 | $25,867,000 | 11.54% |
| NOTTINGHAM ADVISORS, INC. | 171,985 | $3,617,000 | 0.60% |
| Portolan Capital Management | 122,518 | $2,577,000 | 0.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 160,000 | $3,365,000 | 0.33% |
| Rotella Capital Management, Inc. | 18,461 | $388,000 | 0.32% |
| Monashee Investment Management LLC | 28,834 | $606,000 | 0.29% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 335,498 | $7,056,000 | 0.24% |
| BAILARD, INC. | 55,000 | $1,157,000 | 0.18% |